QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Novartis
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01782326
First received: January 30, 2013
Last updated: June 2, 2014
Last verified: June 2014
  Purpose

This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to very severe COPD.


Condition Intervention Phase
Chronic Obstructive Pulmonary Disease (COPD)
Drug: QVA149
Drug: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A 52-week Treatment, Multi-center, Randomized, Double-blind, Double Dummy, Parallel-group, Active Controlled Study to Compare the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) With Salmeterol/Fluticasone on the Rate of Exacerbations in Subjects With Moderate to Very Severe COPD.

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Rate of COPD exacerbations [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    The rate of COPD exacerbations over 52 weeks of treatment.


Secondary Outcome Measures:
  • Time to first COPD exacerbation. [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    The time to the first COPD exacerbation over 52 weeks of treatment.

  • Rate of moderate to severe COPD exacerbations. [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    The rate of moderate to severe COPD exacerbations during 52 weeks of treatment.

  • Time to first moderate to severe COPD exacerbation. [ Time Frame: 52 weeks. ] [ Designated as safety issue: No ]
    The time to the first moderate to severe COPD exacerbation over 52 weeks of treatment.

  • Rate of moderate to severe COPD exacerbations requiring treatment with systemic corticosteroids [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    The rate of moderate to severe COPD exacerbations requiring treatment with systemic corticosteroids over 52 weeks of treatment.

  • Rate of moderate to severe COPD exacerbations requiring treatment with antibiotics [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    The rate of moderate to severe COPD exacerbations requiring treatment with antibiotics during 52 weeks of treatment.

  • Rate of moderate to severe COPD exacerbations requiring hospitalization. [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    The rate of moderate to severe COPD exacerbations requiring hospitalization during 52 weeks of treatment.

  • Rate of moderate to severe COPD exacerbations requiring re-hospitalization within 30 days [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    The rate of moderate to severe COPD exacerbations requiring re-hospitalization within 30 days, during the 52 week treatment period.

  • Time to first moderate to severe COPD exacerbations requiring treatment with systemic corticosteroids [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    The time to first moderate to severe COPD exacerbation requiring treatment with systemic corticosteroids during 52 week of treatment.

  • Time to first moderate to severe COPD exacerbations requiring treatment with antibiotics [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    Time to first COPD exacerbation requiring treatment with antibiotics during 52 weeks of treatment.

  • Time to first moderate to severe COPD exacerbations requiring hospitalization [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    Time to first moderate to severe COPD exacerbation requiring hospitalization during 52 weeks of treatment.

  • Time to first moderate to severe COPD exacerbations requiring re-hospitalization within 30 days [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    Time to first moderate to severe COPD exacerbation requiring re-hospitalization within 30 days, during 52 weeks of treatment.

  • Forced expiratory volume in 1 second [ Time Frame: 1 day ] [ Designated as safety issue: No ]
    Pre-dose trough Forced expiratory volume in 1 second (mean of 23 hours 15 min and 24 hours 45 min) after 1 day of treatment.

  • Forced expiratory volume in 1 second [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    Pre-dose forced expiratory volume in 1 second following 4 weeks of treatment.

  • Forced expiratory volume in 1 second [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Pre-dose trough forced expiratory volume in 1 second following 12 weeks of treatment.

  • Forced expiratory volume in 1 second [ Time Frame: 26 weeks ] [ Designated as safety issue: No ]
    Pre-dose trough Forced expiratory volume in 1 second following 26 weeks of treatment.

  • Forced expiratory volume in 1 second [ Time Frame: 38 weeks ] [ Designated as safety issue: No ]
    Pre-dose trough Forced expiratory volume in 1 second following 38 weeks of treatment.

  • Forced expiratory volume in 1 second [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    Pre-dose trough Forced expiratory volume in 1 second following 52 weeks of treatment.

  • Forced expiratory volume in 1 second AUC (0-12h) [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    Forced expiratory volume in 1 second Area Under the Curve (0-12 hours) following 52 weeks of treatment.

  • Total St. George's Respiratory Questionnaire score [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    Change in health status as reported by patients using the St. George's Respiratory Questionnaire (SGRQ-C), following 4 weeks of treatment.

  • Total St. George's Respiratory Questionnaire score [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Change in health status as reported by patients using the St. George's Respiratory Questionnaire (SGRQ-C), following 12 weeks of treatment.

  • Total St. George's Respiratory Questionnaire score [ Time Frame: 26 weeks ] [ Designated as safety issue: No ]
    Change in health status as reported by patients using the St. George's Respiratory Questionnaire (SGRQ-C), following 26 weeks of treatment.

  • Total St. George's Respiratory Questionnaire score [ Time Frame: 38 weeks ] [ Designated as safety issue: No ]
    Change in health status as reported by patients using the St. George's Respiratory Questionnaire (SGRQ-C), following 38 weeks of treatment.

  • Total St. George's Respiratory Questionnaire score [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    Change in health status as reported by patients using the St. George's Respiratory Questionnaire (SGRQ-C), following 52 weeks of treatment.

  • Number of puffs of rescue medication [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    Rescue medication use (number of puffs) reported by the patients using patient electronic diary following 52 weeks of treatment.


Estimated Enrollment: 3332
Study Start Date: July 2013
Estimated Study Completion Date: September 2015
Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: QVA149 Drug: QVA149
QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI.
Active Comparator: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS) Drug: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)
Salmeterol/fluticasone dry inhalation powder delivered via the Accuhaler device.

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent must be obtained before any assessment is performed
  • Male or female adults aged ≥40 years
  • Patients with stable Chronic Obstructive Pulmonary Disease ( COPD) according to the current GOLD strategy (GOLD 2011)
  • Current or ex-smokers who have a smoking history of at least 10 pack years. (Ten pack-years are defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years)
  • Patients with a post-bronchodilator Forced Expiratory Volume in one second (FEV1) ≥25 and < 60% of the predicted normal value, and post-bronchodilator FEV1/FVC (Forced Vital Capacity) < 0.70 at day -28. (Post refers to 1 hour after sequential inhalation of 84 µg (or equivalent dose) of ipratropium bromide and 400 µg of salbutamol)
  • A documented history of at least 1 COPD exacerbation in the previous 12 months that required treatment with systemic glucocorticosteroids and/or antibiotics
  • Patients taking stable COPD medication (at least 60 days) prior to day 28
  • Patients with an mMRC grade of at least 2 at day 28

Exclusion Criteria:

  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG (human Chorionic Gonadotropin) laboratory test
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential
  • Patients with Type I or uncontrolled Type II diabetes
  • Patients with a history of long QT syndrome or whose QTc measured at day 28 (Fridericia method) is prolonged (>450 ms for males and females) and confirmed by a central assessor. These patients should not be re-screened
  • Patients who have a clinically significant ECG abnormality prior to randomization. (These patients should not be re-screened)
  • Patients who have a clinically significant laboratory abnormality at screening
  • Patients who have clinically significant renal, cardiovascular (such as but not limited to unstable ischemic heart disease, NYHA Class III/IV left ventricular failure, myocardial infarction), arrhythmia (see below for patients with atrial fibrillation), neurological, endocrine, immunological, psychiatric, gastrointestinal, hepatic, or hematological abnormalities which could interfere with the assessment of the efficacy and safety of the study treatment
  • Patients with paroxysmal (e.g. intermittent) atrial fibrillation are excluded
  • Patients with persistent atrial fibrillation as defined by continuous atrial fibrillation for at least 6 months and controlled with a rate control strategy (i.e., selective beta blocker, calcium channel blocker, pacemaker placement, digoxin or ablation therapy) for at least 6 months may be considered for inclusion. In such patients, atrial fibrillation must be present at both pre-randomization visits, with a resting ventricular rate < 100/min. At screening the atrial fibrillation must be confirmed by central reading
  • Patients contraindicated for treatment with, or having a history of reactions/ hypersensitivity to any of the following inhaled drugs, drugs of a similar class or any component thereof: anticholinergic agents, long and short acting beta-2 agonists, sympathomimetic amines, lactose or any of the other excipients of trial medication
  • Patients with a history of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin
  • Patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia or bladder-neck obstruction or moderate to severe renal impairment or urinary retention. Benign Prostatic Hyperplasia (BPH) patients who are stable on treatment can be considered
  • Patients who have not achieved an acceptable spirometry results at screening in accordance with American Thoracic Society (ATS)/European Respiratory Society (ERS) criteria for acceptability (one retest may be performed for patients that don't meet the acceptability criteria)
  • Patients who have had a COPD exacerbation that required treatment with antibiotics and/or systemic corticosteroids and/or hospitalization in the 6 weeks prior to screening
  • Patients who develop a COPD exacerbation of any severity (mild/moderate/severe) between screening and treatment will not be eligible but will be permitted to be re-screened after a minimum of 6 weeks after the resolution of the COPD exacerbation
  • Patients who have had a respiratory tract infection within 4 weeks prior to screening
  • Patients who develop a respiratory tract infection between screening and prior to treatment will not be eligible, but will be permitted to be re-screened 4 weeks after the resolution of the respiratory tract infection
  • Patients requiring long term oxygen therapy prescribed for >12 hours per day
  • Patients with any history of asthma
  • Patients with an onset of respiratory symptoms, including a COPD diagnosis prior to age 40 years
  • Patients with a blood eosinophil count > 600/mm3 at screening
  • Patients with allergic rhinitis who use a H1 antagonist or intra-nasal corticosteroids intermittently (treatment with a stable dose or regimen is permitted)
  • Patients with concomitant pulmonary disease (e.g. lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension)
  • Patients with clinically significant bronchiectasis
  • Patients with a diagnosis of α-1 anti-trypsin deficiency
  • Patients with active pulmonary tuberculosis, unless confirmed by imaging to be no longer active
  • Patients with pulmonary lobectomy or lung volume reduction surgery or lung transplantation
  • Patients participating in or planning to participate in the active phase of a supervised pulmonary rehabilitation program during the study. (Maintenance program is permitted.)
  • Patients receiving any medications in the classes listed in the protocol
  • Patients receiving any COPD related medications in the classes specified in the protocol must undergo the required washout period prior to screening and follow the adjustment to treatment program
  • Use of other investigational drugs/devices (approved or unapproved) at the time of enrollment, or within 30 days or 5 half-lives of screening, whichever is longer
  • Patients unable to use an electronic patient diary and EXACT pro diary
  • Patients unable to use a dry powder inhaler device, Metered Dose Inhaler (MDI) or a pressurized MDI (rescue medication) or comply with the study regimen.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01782326

Contacts
Contact: Novartis Pharmaceuticals +41613241111
Contact: Novartis Pharmaceuticals

  Hide Study Locations
Locations
Argentina
Novartis Investigative Site Not yet recruiting
Caba, Buenos Aires, Argentina, 1122
Novartis Investigative Site Recruiting
Caba, Buenos Aires, Argentina, C1424BSF
Novartis Investigative Site Recruiting
Caba, Buenos Aires, Argentina, C1425BEN
Novartis Investigative Site Recruiting
Caba, Buenos Aires, Argentina, C1122AAK
Novartis Investigative Site Recruiting
Caba, Buenos Aires, Argentina, C1414AIF
Novartis Investigative Site Recruiting
Caba, Buenos Aires, Argentina, B8000XAV
Novartis Investigative Site Recruiting
Caba, Buenos Aires, Argentina, C1056ABJ
Novartis Investigative Site Recruiting
Caba, Buenos Aires, Argentina, C1425BEA
Novartis Investigative Site Not yet recruiting
Florida, Buenos Aires, Argentina, B1602BPD
Novartis Investigative Site Recruiting
Lanus, Buenos Aires, Argentina, B8000XAV
Novartis Investigative Site Recruiting
Mar del Plata, Buenos Aires, Argentina, B7600FZN
Novartis Investigative Site Recruiting
Mar del Plata, Buenos Aires, Argentina, 7600
Novartis Investigative Site Recruiting
Mar del Plata, Buenos Aires, Argentina, B7600DHK
Novartis Investigative Site Not yet recruiting
Quilmes, Buenos Aires, Argentina, B1878FNR
Novartis Investigative Site Not yet recruiting
Ranelagh, Partido de Berazate, Buenos Aires, Argentina, 1884
Novartis Investigative Site Recruiting
Buenos Aires, Capital Federal, Argentina, C1028AAP
Novartis Investigative Site Recruiting
Concepción del Uruguay, Entre Ríos, Argentina, 3260
Novartis Investigative Site Recruiting
Rosario, Santa Fe, Argentina, S2000DBS
Novartis Investigative Site Recruiting
Rosario, Santa Fe, Argentina, S2000AII
Novartis Investigative Site Recruiting
San Miguel de Tucuman, Tucuman, Argentina, 4000
Novartis Investigative Site Recruiting
San Miguel de Tucuman, Tucuman, Argentina, T4000IFL
Novartis Investigative Site Not yet recruiting
Buenos Aires, Argentina, C1125ABE
Novartis Investigative Site Recruiting
Buenos Aires, Argentina, 1425
Novartis Investigative Site Recruiting
Buenos aires, Argentina, C1120AAC
Novartis Investigative Site Recruiting
Ciudad de Buenos Aires, Argentina, C1425AUA
Novartis Investigative Site Not yet recruiting
Cordoba, Argentina, X5003DCE
Novartis Investigative Site Recruiting
Mendoza, Argentina, M5500CBA
Novartis Investigative Site Recruiting
Mendoza, Argentina, 5500
Novartis Investigative Site Recruiting
Salta, Argentina, 4000
Novartis Investigative Site Recruiting
Santa Fe, Argentina, S3000FIL
Austria
Novartis Investigative Site Recruiting
Feldbach, Austria, 8330
Novartis Investigative Site Recruiting
Feldkirch, Austria, 6800
Novartis Investigative Site Recruiting
Graz, Austria, A-8036
Novartis Investigative Site Recruiting
Grieskirchen, Austria, 4710
Novartis Investigative Site Recruiting
Innsbruck, Austria, 6020
Novartis Investigative Site Recruiting
Linz, Austria, 4020
Novartis Investigative Site Recruiting
Salzburg, Austria, 5020
Novartis Investigative Site Recruiting
Thalheim bei Wels, Austria, 4600
Novartis Investigative Site Recruiting
Vienna, Austria, A-1230
Novartis Investigative Site Withdrawn
Vienna, Austria, A-1130
Novartis Investigative Site Recruiting
Wels, Austria, 4600
Belgium
Novartis Investigative Site Recruiting
Aalst, Belgium, 9300
Novartis Investigative Site Completed
Baudour, Belgium, 7331
Novartis Investigative Site Recruiting
Brussel, Belgium, 1090
Novartis Investigative Site Recruiting
Bruxelles, Belgium, 1200
Novartis Investigative Site Recruiting
Bruxelles, Belgium, 1070
Novartis Investigative Site Recruiting
Bruxelles, Belgium, 1000
Novartis Investigative Site Recruiting
Genk, Belgium, 3600
Novartis Investigative Site Recruiting
Gent, Belgium, 9000
Novartis Investigative Site Recruiting
Gilly, Belgium, 6060
Novartis Investigative Site Recruiting
Gosselies, Belgium, 6041
Novartis Investigative Site Recruiting
Hasselt, Belgium, 3500
Novartis Investigative Site Withdrawn
Herentals, Belgium, 2200
Novartis Investigative Site Recruiting
Jambes, Belgium, 5100
Novartis Investigative Site Recruiting
Leuven, Belgium, 3000
Novartis Investigative Site Recruiting
Liège, Belgium, 4000
Novartis Investigative Site Recruiting
Luxembourg, Belgium, 1210
Novartis Investigative Site Recruiting
Malmedy/Bellevaux-Ligneuville, Belgium, 4960
Novartis Investigative Site Withdrawn
Montigny-le-tilleul, Belgium, 6110
Novartis Investigative Site Recruiting
Oostende, Belgium, 8400
Novartis Investigative Site Recruiting
Roeselare, Belgium, 8800
Novartis Investigative Site Recruiting
Turnhout, Belgium, 2300
Novartis Investigative Site Recruiting
Wavre, Belgium, 1301
Brazil
Novartis Investigative Site Not yet recruiting
Salvador, BA, Brazil, 40110-060
Novartis Investigative Site Not yet recruiting
Belo Horizonte, MG, Brazil, 30150-281
Novartis Investigative Site Not yet recruiting
Recife, PE, Brazil, 50920-640
Novartis Investigative Site Not yet recruiting
Rio de Janeiro, RJ, Brazil, 22271-100
Novartis Investigative Site Not yet recruiting
Rio de Janeiro, RJ, Brazil, 22280-020
Novartis Investigative Site Not yet recruiting
Porto Alegre, RS, Brazil, 90035-903
Novartis Investigative Site Not yet recruiting
Porto Alegre, RS, Brazil, 90610-000
Novartis Investigative Site Not yet recruiting
Porto Alegre, RS, Brazil, 90020-090
Novartis Investigative Site Not yet recruiting
Florianopolis, SC, Brazil, 88040-970
Novartis Investigative Site Not yet recruiting
Sao Paulo, SP, Brazil, 05403-000
Bulgaria
Novartis Investigative Site Recruiting
Gabrovo, Bulgaria, 5300
Novartis Investigative Site Recruiting
Pleven, Bulgaria, 5800
Novartis Investigative Site Recruiting
Plovdiv, Bulgaria, 4002
Novartis Investigative Site Recruiting
Ruse, Bulgaria, 7002
Novartis Investigative Site Recruiting
Sofia, Bulgaria, 1431
Novartis Investigative Site Recruiting
Sofia, Bulgaria, 1606
Novartis Investigative Site Recruiting
Stara Zagora, Bulgaria, 6000
Novartis Investigative Site Recruiting
Troyan, Bulgaria, 5600
Novartis Investigative Site Recruiting
Varna, Bulgaria, 9020
Canada, Alberta
Novartis Investigative Site Recruiting
Calgary, Alberta, Canada, T2N 4n1
Canada, British Columbia
Novartis Investigative Site Recruiting
Vancouver, British Columbia, Canada, V5Z 4E1
Canada, New Brunswick
Novartis Investigative Site Recruiting
Moncton, New Brunswick, Canada, E1G 1A7
Canada, Ontario
Novartis Investigative Site Recruiting
Burlington, Ontario, Canada, L7N 3V2
Novartis Investigative Site Recruiting
Downsview, Ontario, Canada, M3N 2Z9
Novartis Investigative Site Withdrawn
Toronto, Ontario, Canada, M5G1N8
Novartis Investigative Site Recruiting
Toronto, Ontario, Canada, M5T 3A9
Canada, Quebec
Novartis Investigative Site Not yet recruiting
Fleurimont, Quebec, Canada, J1H 5N4
Novartis Investigative Site Recruiting
La Malbaie, Quebec, Canada, G5A 1W7
Novartis Investigative Site Withdrawn
Laval, Quebec, Canada, H7S 2M5
Novartis Investigative Site Recruiting
Mirabel, Quebec, Canada, J7J 2K8
Novartis Investigative Site Withdrawn
Montreal, Quebec, Canada, H3T 1E2
Novartis Investigative Site Withdrawn
Montreal, Quebec, Canada, H4J 1C5
Novartis Investigative Site Recruiting
Montreal, Quebec, Canada, H3G 1L5
Novartis Investigative Site Recruiting
Montreal, Quebec, Canada, H2R 1V6
Novartis Investigative Site Recruiting
St-Charles-Borromée, Quebec, Canada, J6E 2B4
Canada
Novartis Investigative Site Recruiting
Quebec, Canada, G1N 4V3
Chile
Novartis Investigative Site Recruiting
Quillota, Chile, 2260877
Novartis Investigative Site Not yet recruiting
Santiago, Chile, 8910131
Novartis Investigative Site Withdrawn
Santiago, Chile
Novartis Investigative Site Recruiting
Santiago, Chile
China, Beijing
Novartis Investigative Site Recruiting
Beijing, Beijing, China, 100023
Novartis Investigative Site Not yet recruiting
Beijing, Beijing, China, 100730
China, Guangdong
Novartis Investigative Site Recruiting
Guang Zhou, Guangdong, China, 510120
China, Guangxi
Novartis Investigative Site Not yet recruiting
Nanning, Guangxi, China, 530021
China, Hainan
Novartis Investigative Site Recruiting
Haikou, Hainan, China, 570311
China, Hebei
Novartis Investigative Site Recruiting
Shijiazhuang, Hebei, China, 050000
Novartis Investigative Site Not yet recruiting
Shijiazhuang, Hebei, China, 050051
China, Hunan
Novartis Investigative Site Recruiting
Changsha, Hunan, China, 410003
China, Jiangsu
Novartis Investigative Site Recruiting
Nanjing, Jiangsu, China, 210029
Novartis Investigative Site Recruiting
Suzhou, Jiangsu, China, 215006
China, Jiangxi
Novartis Investigative Site Recruiting
Nanchang, Jiangxi, China, 330006
China, Liaoning
Novartis Investigative Site Recruiting
Shengyang, Liaoning, China, 110016
China, Shanghai
Novartis Investigative Site Recruiting
Shanghai, Shanghai, China, 200433
China, Shanxi
Novartis Investigative Site Recruiting
Xi'an, Shanxi, China, 710032
China, Sichuan
Novartis Investigative Site Recruiting
Chengdu, Sichuan, China, 610041
China, Zhejiang
Novartis Investigative Site Not yet recruiting
Hangzhou, Zhejiang, China, 310003
Novartis Investigative Site Recruiting
Hangzhou, Zhejiang, China, 310006
China
Novartis Investigative Site Recruiting
Beijing, China, 100050
Novartis Investigative Site Recruiting
Chongqing, China, 400038
Novartis Investigative Site Recruiting
Chongqing, China, 400037
Novartis Investigative Site Recruiting
Guang Zhou, China, 510010
Novartis Investigative Site Not yet recruiting
Shanghai, China, 200025
Novartis Investigative Site Recruiting
Tianjin, China, 300052
Colombia
Novartis Investigative Site Recruiting
Bogota, Cundinamarca, Colombia
Novartis Investigative Site Recruiting
Floridablanca, Santander, Colombia, 57-7
Novartis Investigative Site Recruiting
Armenia, Colombia
Novartis Investigative Site Recruiting
Medellín, Colombia
Croatia
Novartis Investigative Site Recruiting
Karlovac, Croatia, 47000
Novartis Investigative Site Recruiting
Zagreb, Croatia, 10000
Novartis Investigative Site Recruiting
Zagreb, Croatia, 10 000
Czech Republic
Novartis Investigative Site Recruiting
Benesov, Czech Republic, 256 30
Novartis Investigative Site Recruiting
Cesky Krumlov, Czech Republic, 381 01
Novartis Investigative Site Recruiting
Cvikov, Czech Republic, 471 54
Novartis Investigative Site Recruiting
Jindrichuv Hradec III, Czech Republic, 377 01
Novartis Investigative Site Recruiting
Liberec, Czech Republic, 460 01
Novartis Investigative Site Recruiting
Melnik, Czech Republic, 267 01
Novartis Investigative Site Not yet recruiting
Olomouc, Czech Republic, 775 20
Novartis Investigative Site Recruiting
Ostrava, Czech Republic, 708 68
Novartis Investigative Site Recruiting
Ostrava - Hrabuvka, Czech Republic, 70030
Novartis Investigative Site Recruiting
Pardubice, Czech Republic, 530 09
Novartis Investigative Site Recruiting
Prague 4, Czech Republic, 142 00
Novartis Investigative Site Recruiting
Praha 10, Czech Republic, 108 00
Novartis Investigative Site Recruiting
Praha 5, Czech Republic, 158 00
Novartis Investigative Site Recruiting
Praha 6, Czech Republic, 169 00
Novartis Investigative Site Recruiting
Praha 6 - Repy, Czech Republic, 163 00
Novartis Investigative Site Recruiting
Strakonice, Czech Republic, 38601
Novartis Investigative Site Recruiting
Teplice, Czech Republic, 415 01
Novartis Investigative Site Recruiting
Zatec, Czech Republic, 438 01
Denmark
Novartis Investigative Site Recruiting
Aalborg, Denmark, DK-9100
Novartis Investigative Site Recruiting
Copenhagen NV, Denmark, DK-2400
Novartis Investigative Site Recruiting
Hellerup, Denmark, DK-2900
Novartis Investigative Site Recruiting
Hvidovre, Denmark, DK-2650
Novartis Investigative Site Recruiting
Næstved, Denmark, 4700
Novartis Investigative Site Recruiting
Roskilde, Denmark, DK-4000
Novartis Investigative Site Recruiting
Silkeborg, Denmark, 8600
Novartis Investigative Site Recruiting
Sønderborg, Denmark, DK-6400
Novartis Investigative Site Recruiting
Århus, Denmark, DK-8000
Egypt
Novartis Investigative Site Withdrawn
Alexandria, Egypt, 21131
Estonia
Novartis Investigative Site Recruiting
Tallinn, Estonia, 13619
Novartis Investigative Site Recruiting
Tallinn, Estonia, 13419
Novartis Investigative Site Recruiting
Tartu, Estonia, 51014
Finland
Novartis Investigative Site Recruiting
Helsinki, Finland, 00290
Novartis Investigative Site Recruiting
HUS, Finland, 00029
Novartis Investigative Site Recruiting
Jyvaskyla, Finland, 40100
Novartis Investigative Site Recruiting
Kuopio, Finland, FIN-70211
Novartis Investigative Site Recruiting
Pori, Finland, FIN-28500
Novartis Investigative Site Recruiting
Turku, Finland, FIN-20100
France
Novartis Investigative Site Recruiting
Angers, France, 49000
Novartis Investigative Site Withdrawn
Angers, France, 49 000
Novartis Investigative Site Not yet recruiting
Antibes, France, 06606
Novartis Investigative Site Recruiting
Beuvry, France, 62660
Novartis Investigative Site Withdrawn
Bourges, France, 18000
Novartis Investigative Site Recruiting
Briis Sous Forges, France, 91640
Novartis Investigative Site Recruiting
Cournonterral, France, 34660
Novartis Investigative Site Withdrawn
Creteil, France, 94010
Novartis Investigative Site Recruiting
Lyon cedex 04, France, 69317
Novartis Investigative Site Recruiting
Metz, France, 57085
Novartis Investigative Site Not yet recruiting
Montpellier, France, 34059
Novartis Investigative Site Recruiting
Nantes, France, 44000
Novartis Investigative Site Recruiting
Nantes, France, 44300
Novartis Investigative Site Recruiting
Nimes Cedex, France, 30029
Novartis Investigative Site Recruiting
Pessac, France, 33604
Novartis Investigative Site Recruiting
Reims, France, 51092
Novartis Investigative Site Recruiting
St Genis des Fontaines, France, 66740
Germany
Novartis Investigative Site Recruiting
Koblenz, NRW, Germany, 56068
Novartis Investigative Site Recruiting
Cottbus, Sachsen, Germany, 03050
Novartis Investigative Site Recruiting
Aschaffenburg, Germany, 63739
Novartis Investigative Site Recruiting
Bad Woerishofen, Germany, 86825
Novartis Investigative Site Recruiting
Bamberg, Germany, 96049
Novartis Investigative Site Recruiting
Berlin, Germany, 13581
Novartis Investigative Site Recruiting
Berlin, Germany, 13086
Novartis Investigative Site Recruiting
Berlin, Germany, 10117
Novartis Investigative Site Recruiting
Berlin, Germany, 12099
Novartis Investigative Site Recruiting
Berlin, Germany, 13156
Novartis Investigative Site Recruiting
Berlin, Germany, 10969
Novartis Investigative Site Recruiting
Berlin, Germany, 10119
Novartis Investigative Site Recruiting
Berlin, Germany, 12043
Novartis Investigative Site Recruiting
Berlin, Germany, 10367
Novartis Investigative Site Recruiting
Berlin, Germany, 13125
Novartis Investigative Site Recruiting
Berlin, Germany, 10789
Novartis Investigative Site Recruiting
Berlin, Germany, 12203
Novartis Investigative Site Recruiting
Bielefeld, Germany, 33617
Novartis Investigative Site Recruiting
Bochum, Germany, 44787
Novartis Investigative Site Recruiting
Bonn, Germany, 53123
Novartis Investigative Site Recruiting
Bonn, Germany, 53119
Novartis Investigative Site Recruiting
Delitzsch, Germany, 04509
Novartis Investigative Site Recruiting
Dresden, Germany, 01307
Novartis Investigative Site Recruiting
Duisburg, Germany, 47057
Novartis Investigative Site Recruiting
Erlangen, Germany, 91052
Novartis Investigative Site Recruiting
Frankfurt, Germany, 60389
Novartis Investigative Site Recruiting
Frankfurt, Germany, 60596
Novartis Investigative Site Recruiting
Freudenberg, Germany, 57258
Novartis Investigative Site Recruiting
Gauting, Germany, 82131
Novartis Investigative Site Recruiting
Geesthacht, Germany, 12502
Novartis Investigative Site Withdrawn
Gelsenkirchen, Germany, 45879
Novartis Investigative Site Not yet recruiting
Gummersbach, Germany, 51643
Novartis Investigative Site Recruiting
Hagen, Germany, 59065
Novartis Investigative Site Recruiting
Halle, Germany, 06108
Novartis Investigative Site Recruiting
Hamburg, Germany, 20354
Novartis Investigative Site Recruiting
Hamburg, Germany, 22299
Novartis Investigative Site Recruiting
Hamburg, Germany, 20253
Novartis Investigative Site Recruiting
Hannover, Germany, 30159
Novartis Investigative Site Recruiting
Hannover Münden, Germany, 34346
Novartis Investigative Site Recruiting
Heidelberg, Germany, 69126
Novartis Investigative Site Recruiting
Kassel, Germany, 34121
Novartis Investigative Site Recruiting
Koeln, Germany, 51069
Novartis Investigative Site Recruiting
Landsberg, Germany, 86899
Novartis Investigative Site Recruiting
Leipzig, Germany, 04207
Novartis Investigative Site Recruiting
Leipzig, Germany, 04357
Novartis Investigative Site Recruiting
Leipzig, Germany, 04275
Novartis Investigative Site Recruiting
Leipzig, Germany, 04103
Novartis Investigative Site Recruiting
Lübeck, Germany, 23558
Novartis Investigative Site Recruiting
Lübeck, Germany, 23552
Novartis Investigative Site Recruiting
Marburg, Germany, 35037
Novartis Investigative Site Recruiting
Minden, Germany, 32423
Novartis Investigative Site Withdrawn
Muenchen, Germany, 81677
Novartis Investigative Site Recruiting
München, Germany, 80335
Novartis Investigative Site Recruiting
Neu Isenburg, Germany, 63263
Novartis Investigative Site Recruiting
Neumünster, Germany, 24534
Novartis Investigative Site Recruiting
Oranienburg, Germany, 16515
Novartis Investigative Site Recruiting
Peine, Germany, 31224
Novartis Investigative Site Recruiting
Potsdam, Germany, 14469
Novartis Investigative Site Recruiting
Potsdam, Germany, 14467
Novartis Investigative Site Recruiting
Prien a. Chiemsee, Germany, 83209
Novartis Investigative Site Recruiting
Ratingen, Germany, 40878
Novartis Investigative Site Terminated
Reinfeld, Germany, 23858
Novartis Investigative Site Recruiting
Rüdersdorf, Germany, 15562
Novartis Investigative Site Recruiting
Schleswig, Germany, 24837
Novartis Investigative Site Recruiting
Schwabach, Germany, 91126
Novartis Investigative Site Recruiting
Solingen, Germany, 42651
Novartis Investigative Site Recruiting
Stade, Germany, 21680
Novartis Investigative Site Recruiting
Teuchern, Germany, 06682
Novartis Investigative Site Not yet recruiting
Ulm, Germany, 89081
Novartis Investigative Site Recruiting
Ulm, Germany, 89073
Novartis Investigative Site Withdrawn
Vöhringen, Germany, 89269
Novartis Investigative Site Recruiting
Warendorf, Germany, 48231
Novartis Investigative Site Recruiting
Weinheim, Germany, 69469
Novartis Investigative Site Recruiting
Wissen, Germany, 57537
Novartis Investigative Site Recruiting
Witten, Germany, 58452
Greece
Novartis Investigative Site Recruiting
Athens, GR, Greece, 115 27
Novartis Investigative Site Recruiting
Athens, GR, Greece, 124 62
Novartis Investigative Site Recruiting
Athens, GR, Greece, 106 76
Novartis Investigative Site Recruiting
Larissa, GR, Greece, 411 10
Novartis Investigative Site Recruiting
Thessaloniki, GR, Greece, 564 03
Novartis Investigative Site Recruiting
Athens, Greece, GR 115 27
Novartis Investigative Site Not yet recruiting
Athens, Neo Faliro, Greece, GR 18547
Novartis Investigative Site Recruiting
Heraklion Crete, Greece, GR 711 10
Novartis Investigative Site Recruiting
Rethymno, Greece, 74100
Novartis Investigative Site Recruiting
Serres, Greece, GR 62 100
Novartis Investigative Site Recruiting
Thessaloniki, Greece, GR 570 10
Guatemala
Novartis Investigative Site Recruiting
Guatemala City, Guatemala, 01010
Novartis Investigative Site Withdrawn
Guatemala City, Guatemala, 01010
Novartis Investigative Site Recruiting
Guatemala City, Guatemala, 01011
Hong Kong
Novartis Investigative Site Recruiting
Kowloon, Hong Kong
Novartis Investigative Site Recruiting
New Territories, Hong Kong
Novartis Investigative Site Not yet recruiting
Pokfulam, Hong Kong
Hungary
Novartis Investigative Site Recruiting
Budapest, Hungary, 1145
Novartis Investigative Site Recruiting
Budapest, Hungary, 1125
Novartis Investigative Site Recruiting
Budapest, Hungary, 1121
Novartis Investigative Site Recruiting
Deszk, Hungary, 6772
Novartis Investigative Site Recruiting
Komarom, Hungary, 2900
Novartis Investigative Site Recruiting
Torokbalint, Hungary, 2045
Iceland
Novartis Investigative Site Recruiting
Reykjavik, Iceland, IS-109
India
Novartis Investigative Site Recruiting
Hyderabad, Andhra Pradesh, India, 500004
Novartis Investigative Site Recruiting
Vijayawada, Andhra Pradesh, India, 520 002
Novartis Investigative Site Recruiting
Visakhapatnam, Andhra Pradesh, India, 530002
Novartis Investigative Site Not yet recruiting
New Delhi, Delhi, India, 110070
Novartis Investigative Site Recruiting
Ahmedabad, Gujarat, India, 380 060
Novartis Investigative Site Recruiting
Ahmedabad, Gujarat, India, 380 008
Novartis Investigative Site Recruiting
Gurgaon, Haryana, India, 122 002
Novartis Investigative Site Withdrawn
Bangalore, Karnataka, India, 560054
Novartis Investigative Site Not yet recruiting
Bangalore, Karnataka, India, 560004
Novartis Investigative Site Recruiting
Mangalore, Karnataka, India, 575001
Novartis Investigative Site Recruiting
Manipal, Karnataka, India, 576 104
Novartis Investigative Site Recruiting
Aurangabad, Maharashtra, India, 431 001
Novartis Investigative Site Recruiting
Nagpur, Maharashtra, India, 440010
Novartis Investigative Site Recruiting
Ludhiana, Punjab, India, 141001
Novartis Investigative Site Recruiting
Jaipur, Rajasthan, India, 302004
Novartis Investigative Site Recruiting
Chennai, Tamil Nadu, India, 641037
Novartis Investigative Site Recruiting
Coimbatore, Tamil Nadu, India, 641037
Novartis Investigative Site Recruiting
Coimbatore, Tamil Nadu, India, 641 045.
Novartis Investigative Site Recruiting
Coimbatore, Tamilnadu, India, 641 018
Novartis Investigative Site Not yet recruiting
Aligarh, Uttar Pradesh, India, 202 002
Novartis Investigative Site Recruiting
Kolkata, West Bengal, India, 700 107
Novartis Investigative Site Withdrawn
Kolkata, West Bengal, India, 700017
Novartis Investigative Site Not yet recruiting
Bangalore, India, 560 034
Italy
Novartis Investigative Site Recruiting
Ancona, AN, Italy, 60020
Novartis Investigative Site Recruiting
Cassano delle Murge, BA, Italy, 70020
Novartis Investigative Site Recruiting
Crema, CR, Italy, 26013
Novartis Investigative Site Recruiting
Foggia, FG, Italy, 71100
Novartis Investigative Site Recruiting
Firenze, FI, Italy, 50100
Novartis Investigative Site Recruiting
Genova, GE, Italy, 16132
Novartis Investigative Site Recruiting
Milano, MI, Italy, 20126
Novartis Investigative Site Recruiting
Pavullo nel Frignano, MO, Italy, 41026
Novartis Investigative Site Recruiting
Palermo, PA, Italy, 90146
Novartis Investigative Site Recruiting
Cittadella, PD, Italy, 35013
Novartis Investigative Site Recruiting
Pisa, PI, Italy, 56124
Novartis Investigative Site Recruiting
Pordenone, PN, Italy, 33170
Novartis Investigative Site Recruiting
Parma, PR, Italy, 43100
Novartis Investigative Site Recruiting
Pavia, PV, Italy, 27100
Novartis Investigative Site Recruiting
Reggio Emilia, RE, Italy, 42123
Novartis Investigative Site Recruiting
Cuasso al Monte, VA, Italy, 21050
Novartis Investigative Site Recruiting
Tradate, VA, Italy, 21049
Novartis Investigative Site Recruiting
Negrar, VR, Italy, 37024
Novartis Investigative Site Recruiting
Napoli, Italy, 80131
Japan
Novartis Investigative Site Recruiting
Komaki-city, Aichi, Japan, 485-0041
Novartis Investigative Site Recruiting
Nagoya, Aichi, Japan, 457-8511
Novartis Investigative Site Recruiting
Seto-city, Aichi, Japan, 489-8642
Novartis Investigative Site Recruiting
Toyoake, Aichi, Japan, 470-1192
Novartis Investigative Site Recruiting
Yanagawa, Fukuoka, Japan, 832-0059
Novartis Investigative Site Recruiting
Asahikawa-city, Hokkaido, Japan, 070-8644
Novartis Investigative Site Recruiting
Obihiro, Hokkaido, Japan, 080-0805
Novartis Investigative Site Recruiting
Sapporo, Hokkaido, Japan, 062-8618
Novartis Investigative Site Recruiting
Sapporo-city, Hokkaido, Japan, 060-8648
Novartis Investigative Site Recruiting
Himeji-city, Hyogo, Japan, 672-8064
Novartis Investigative Site Recruiting
Sakaide, Kagawa, Japan, 762-0031
Novartis Investigative Site Recruiting
Takamatsu, Kagawa, Japan, 760-8538
Novartis Investigative Site Recruiting
Kawasaki, Kanagawa, Japan, 210-0852
Novartis Investigative Site Recruiting
Koshi-city, Kumamoto, Japan, 861-1196
Novartis Investigative Site Recruiting
Kyoto-city, Kyoto, Japan, 606-8507
Novartis Investigative Site Recruiting
Matsusaka-city, Mie, Japan, 515-8544
Novartis Investigative Site Recruiting
Sendai-city, Miyagi, Japan, 980-8574
Novartis Investigative Site Recruiting
Kishiwada, Osaka, Japan, 596-8501
Novartis Investigative Site Recruiting
Koshigaya-city, Saitama, Japan, 343-0851
Novartis Investigative Site Recruiting
Hamamatsu, Shizuoka, Japan, 430-8525
Novartis Investigative Site Recruiting
Hamamatsu, Shizuoka, Japan, 434-8511
Novartis Investigative Site Recruiting
Iwata, Shizuoka, Japan, 438-8550
Novartis Investigative Site Recruiting
Bunkyo-ku, Tokyo, Japan, 113-8431
Novartis Investigative Site Recruiting
Chuo-ku, Tokyo, Japan, 103-0027
Novartis Investigative Site Recruiting
Itabashi-ku, Tokyo, Japan, 173-8610
Novartis Investigative Site Recruiting
Kiyose-city, Tokyo, Japan, 204-8585
Novartis Investigative Site Recruiting
Meguro, Tokyo, Japan, 152-8902
Novartis Investigative Site Recruiting
Fukuoka, Japan, 811-1394
Novartis Investigative Site Recruiting
Fukuoka, Japan, 812-0033
Novartis Investigative Site Recruiting
Kochi, Japan, 780-8077
Korea, Republic of
Novartis Investigative Site Recruiting
Dong-gu, Gwangju, Korea, Republic of, 501-575
Novartis Investigative Site Recruiting
Bucheon-Si, Gyeonggi-Do, Korea, Republic of
Novartis Investigative Site Recruiting
Jeonju-si, Jeollabuk-do, Korea, Republic of, 561-712
Novartis Investigative Site Recruiting
Seoul, Korea, Korea, Republic of, 110 744
Novartis Investigative Site Recruiting
Incheon, Korea, Republic of, 403-010
Novartis Investigative Site Withdrawn
Seoul, Korea, Republic of, 137-701
Novartis Investigative Site Recruiting
Seoul, Korea, Republic of, 136 705
Novartis Investigative Site Recruiting
Seoul, Korea, Republic of, 130-702
Novartis Investigative Site Recruiting
Seoul, Korea, Republic of, 137-701
Novartis Investigative Site Recruiting
Seoul, Korea, Republic of, 156-755
Novartis Investigative Site Recruiting
Seoul, Korea, Republic of, 130-709
Latvia
Novartis Investigative Site Recruiting
Riga, LV, Latvia, LV-1038
Novartis Investigative Site Recruiting
Daugavpils, Latvia, LV-5401
Novartis Investigative Site Withdrawn
Kraslava, Latvia, 5601
Novartis Investigative Site Recruiting
Riga, Latvia, 1002
Lithuania
Novartis Investigative Site Recruiting
Kaunas, LT, Lithuania, 50128
Novartis Investigative Site Recruiting
Vilnius, LT, Lithuania, 01117
Novartis Investigative Site Recruiting
Alytus, Lithuania, LT-62114
Novartis Investigative Site Recruiting
Kaunas, Lithuania, 50009
Novartis Investigative Site Recruiting
Kaunas, Lithuania, LT-45130
Novartis Investigative Site Recruiting
Kaunas, Lithuania, 44313
Novartis Investigative Site Recruiting
Klaipeda, Lithuania, LT-92231
Novartis Investigative Site Recruiting
Klaipeda, Lithuania, 92288
Novartis Investigative Site Withdrawn
Utena, Lithuania, LT-28151
Novartis Investigative Site Recruiting
Vilnius, Lithuania, 06122
Novartis Investigative Site Recruiting
Vilnius, Lithuania, LT-08661
Novartis Investigative Site Withdrawn
Vilnius, Lithuania, LT-08661
Mexico
Novartis Investigative Site Recruiting
Mexico, Distrito Federal, Mexico, 14050
Novartis Investigative Site Recruiting
México, Distrito Federal, Mexico, 14080
Novartis Investigative Site Recruiting
Guadalajara Jalisco, Jalisco, Mexico, 44220
Novartis Investigative Site Recruiting
Zapopan, Jalisco, Mexico, 45200
Novartis Investigative Site Recruiting
Aguascalientes, Mexico, 20230
Novartis Investigative Site Recruiting
Mexico D.F., Mexico, 06726
Novartis Investigative Site Recruiting
Puebla, Mexico, 72000
Netherlands
Novartis Investigative Site Recruiting
Almelo, Netherlands, 7609 PP
Novartis Investigative Site Recruiting
Assen, Netherlands, 9401 RK
Novartis Investigative Site Recruiting
Breda, Netherlands, 4818 CK
Novartis Investigative Site Recruiting
Eindhoven, Netherlands, 5623 EJ
Novartis Investigative Site Recruiting
Enschede, Netherlands, 7513 ER
Novartis Investigative Site Recruiting
Geldrop, Netherlands, 5664 EH
Novartis Investigative Site Recruiting
Groningen, Netherlands, 9728 NT
Novartis Investigative Site Recruiting
Harderwijk, Netherlands, 3840 AC
Novartis Investigative Site Withdrawn
Hengelo, Netherlands, 7555 DL
Novartis Investigative Site Recruiting
Zutphen, Netherlands, 7207 AE
Norway
Novartis Investigative Site Withdrawn
Elverum, Norway, 2408
Novartis Investigative Site Recruiting
Follebu, Norway, 2656
Novartis Investigative Site Recruiting
Hønefoss, Norway, 3515
Novartis Investigative Site Recruiting
Kløfta, Norway, 2040
Novartis Investigative Site Recruiting
Kongsvinger, Norway, 2212
Novartis Investigative Site Withdrawn
Sandvika, Norway, 1337
Novartis Investigative Site Recruiting
Skedsmokorset, Norway, 2020
Novartis Investigative Site Recruiting
Stavanger, Norway, 4005
Novartis Investigative Site Recruiting
Svelvik, Norway, 3060
Novartis Investigative Site Terminated
Trondheim, Norway, 7006
Philippines
Novartis Investigative Site Recruiting
Lipa City, Batangas, Philippines, 4217
Novartis Investigative Site Recruiting
Bulacan, Philippines, 3020
Novartis Investigative Site Recruiting
Quezon City, Philippines, 1100
Poland
Novartis Investigative Site Recruiting
Bialystok, Poland, 15-044
Novartis Investigative Site Recruiting
Bialystok, Poland, 15-010
Novartis Investigative Site Recruiting
Lodz, Poland, 90-153
Novartis Investigative Site Recruiting
Pila, Poland, 64-920
Novartis Investigative Site Recruiting
Poznan, Poland, 60-569
Novartis Investigative Site Recruiting
Sopot, Poland, 81-741
Novartis Investigative Site Recruiting
Wroclaw, Poland, 51-162
Portugal
Novartis Investigative Site Recruiting
Almada, Portugal, 2801-951
Novartis Investigative Site Recruiting
Barcelos, Portugal, 4754-909
Novartis Investigative Site Recruiting
Braga, Portugal, 4710-243
Novartis Investigative Site Recruiting
Coimbra, Portugal, 3041-853
Novartis Investigative Site Recruiting
Lisboa, Portugal, 1169-024
Novartis Investigative Site Recruiting
Lisboa, Portugal, 1769-001
Novartis Investigative Site Recruiting
Porto, Portugal, 4200-319
Novartis Investigative Site Recruiting
Torres Vedras, Portugal, 2560-324
Novartis Investigative Site Recruiting
Vila Nova de Gaia, Portugal, 4434-502
Novartis Investigative Site Recruiting
Viseu, Portugal, 3504-509
Novartis Investigative Site Recruiting
Xira, Portugal, 2600-009
Romania
Novartis Investigative Site Recruiting
Bucharest, District 1, Romania, 10457
Novartis Investigative Site Recruiting
Bucharest, District 3, Romania, 030317
Novartis Investigative Site Recruiting
Craiova, Dolj, Romania, 200515
Novartis Investigative Site Recruiting
Iasi, Jud. Iasi, Romania, 700115
Novartis Investigative Site Recruiting
Arad, Romania, 310013
Novartis Investigative Site Recruiting
Arad, Romania, 310086
Novartis Investigative Site Recruiting
Brasov, Romania
Novartis Investigative Site Recruiting
Bucharest, Romania
Novartis Investigative Site Recruiting
Bucharest, Romania, 050159
Novartis Investigative Site Recruiting
Bucharest, Romania, 060011
Novartis Investigative Site Recruiting
Bucuresti, Romania, 50159
Novartis Investigative Site Recruiting
Cluj-Napoca, Romania, 400371
Novartis Investigative Site Recruiting
Deva, Romania, 330162
Novartis Investigative Site Recruiting
Deva, Romania, 330084
Novartis Investigative Site Recruiting
Iasi, Romania, 700305
Novartis Investigative Site Recruiting
Oradea, Romania, 410051
Novartis Investigative Site Recruiting
Oradea, Romania, 410176
Novartis Investigative Site Recruiting
Targu Mures, Romania, 540072
Russian Federation
Novartis Investigative Site Recruiting
Barnaul, Russian Federation, 656045
Novartis Investigative Site Recruiting
Chelyabinsk, Russian Federation, 454021
Novartis Investigative Site Recruiting
Kazan, Russian Federation, 420012
Novartis Investigative Site Not yet recruiting
Moscow, Russian Federation, 127473
Novartis Investigative Site Recruiting
N.Novgorod, Russian Federation, 603126
Novartis Investigative Site Recruiting
Rostov-on-Don, Russian Federation, 344090
Novartis Investigative Site Recruiting
Ryazan, Russian Federation, 390026
Novartis Investigative Site Recruiting
Saratov, Russian Federation, 410012
Novartis Investigative Site Recruiting
Tver, Russian Federation, 170036
Novartis Investigative Site Recruiting
Ufa, Russian Federation, 450000
Novartis Investigative Site Recruiting
Yaroslavl, Russian Federation, 150030
Serbia
Novartis Investigative Site Recruiting
Belgrade, Serbia, 11080
Novartis Investigative Site Recruiting
Belgrade, Serbia, 11000
Novartis Investigative Site Recruiting
Knez Selo, Serbia, 18204
Novartis Investigative Site Recruiting
Kragujevac, Serbia, 34000
Slovakia
Novartis Investigative Site Recruiting
Bardejov, Slovak Republic, Slovakia, 085 01
Novartis Investigative Site Recruiting
Bojnice, Slovak Republic, Slovakia, 972 01
Novartis Investigative Site Completed
Bratislava, Slovak Republic, Slovakia, 821 06
Novartis Investigative Site Recruiting
Humenné, Slovak republic, Slovakia, 066 01
Novartis Investigative Site Recruiting
Kosice, Slovak republic, Slovakia, 04001
Novartis Investigative Site Recruiting
Liptovsky Hradok, Slovak Republic, Slovakia, 033 01
Novartis Investigative Site Recruiting
Partizanske, Slovak Republic, Slovakia, 958 01
Novartis Investigative Site Recruiting
Námestovo, Slovensko, Slovakia, 02901
Novartis Investigative Site Recruiting
Bratislava, Slovakia, 84104
Novartis Investigative Site Recruiting
Kosice, Slovakia, 040 01
Novartis Investigative Site Recruiting
Lucenec, Slovakia, 98439
Novartis Investigative Site Recruiting
Martin, Slovakia, 036 59
Novartis Investigative Site Recruiting
Nove Zamky, Slovakia, 940 01
Novartis Investigative Site Recruiting
Poprad, Slovakia, 058 01
Novartis Investigative Site Recruiting
Povazska Bystrica, Slovakia, 017 01
Novartis Investigative Site Recruiting
Spisská Nová Ves, Slovakia, 052 01
South Africa
Novartis Investigative Site Recruiting
Berea, Durban, South Africa, 4001
Novartis Investigative Site Recruiting
Sandton, Gauteng, South Africa, 2057
Novartis Investigative Site Withdrawn
Amanzimtoti, South Africa, 4126
Novartis Investigative Site Recruiting
Cape Town, South Africa, 7925
Novartis Investigative Site Recruiting
Cape Town, South Africa, 7500
Novartis Investigative Site Recruiting
Cape Town, South Africa, 7531
Novartis Investigative Site Recruiting
Cape Town, South Africa, 7505
Novartis Investigative Site Recruiting
Gatesville, South Africa, 7764
Novartis Investigative Site Recruiting
Port Elizabeth, South Africa, 6014
Novartis Investigative Site Recruiting
Pretoria, South Africa, 0181
Novartis Investigative Site Recruiting
Pretoria, South Africa, 0132
Spain
Novartis Investigative Site Recruiting
Cordoba, Andalucia, Spain, 14004
Novartis Investigative Site Withdrawn
Loja, Andalucia, Spain, 18300
Novartis Investigative Site Recruiting
Malaga, Andalucia, Spain, 29010
Novartis Investigative Site Recruiting
Sanlúcar de Barrameda, Andalucia, Spain, 11540
Novartis Investigative Site Recruiting
Oviedo (Asturias), Asturias, Spain, 33006
Novartis Investigative Site Recruiting
Torrelavega, Cantabria, Spain, 39300
Novartis Investigative Site Withdrawn
Vila-real, Castellon, Spain, 12540
Novartis Investigative Site Recruiting
Burgos, Castilla y Leon, Spain, 09006
Novartis Investigative Site Recruiting
Ponferrada, Castilla y Leon, Spain, 24400
Novartis Investigative Site Not yet recruiting
Salamanca, Castilla y Leon, Spain, 37007
Novartis Investigative Site Recruiting
Valladolid, Castilla y Leon, Spain, 47011
Novartis Investigative Site Recruiting
Barcelona, Catalunya, Spain, 08035
Novartis Investigative Site Recruiting
Barcelona, Catalunya, Spain, 08003
Novartis Investigative Site Recruiting
Barcelona, Cataluña, Spain, 08024
Novartis Investigative Site Recruiting
Barcelona, Cataluña, Spain, 08041
Novartis Investigative Site Recruiting
Salt, Cataluña, Spain, 17190
Novartis Investigative Site Recruiting
Alicante, Comunidad Valenciana, Spain, 03550
Novartis Investigative Site Recruiting
Alzira, Comunidad Valenciana, Spain, 46600
Novartis Investigative Site Recruiting
Castellon, Comunidad Valenciana, Spain, 12005
Novartis Investigative Site Recruiting
Valencia, Comunidad Valenciana, Spain, 46014
Novartis Investigative Site Recruiting
Mérida, Extremadura, Spain, 06800
Novartis Investigative Site Withdrawn
Pontevedra, Galicia, Spain, 36071
Novartis Investigative Site Recruiting
Pozuelo de Alarcón, Madrid, Spain, 28223
Novartis Investigative Site Recruiting
Cartagena, Murcia, Spain, 30202
Novartis Investigative Site Recruiting
Pamplona, Navarra, Spain, 31008
Novartis Investigative Site Recruiting
Baracaldo, Pais Vasco, Spain, 48903
Novartis Investigative Site Recruiting
Barcelona, Spain, 08022
Novartis Investigative Site Recruiting
Madrid, Spain, 28046
Novartis Investigative Site Not yet recruiting
Madrid, Spain, 28942
Novartis Investigative Site Recruiting
Madrid, Spain, 28029
Novartis Investigative Site Recruiting
Madrid, Spain, 28031
Novartis Investigative Site Withdrawn
Salamanca, Spain, 37003
Sweden
Novartis Investigative Site Withdrawn
Kristianstad, Sweden, 291 85
Novartis Investigative Site Recruiting
Luleå, Sweden, SE-971 80
Novartis Investigative Site Recruiting
Lund, Sweden, SE-221 85
Novartis Investigative Site Recruiting
Skene, Sweden, 511 62
Novartis Investigative Site Withdrawn
Skovde, Sweden, 541 85
Novartis Investigative Site Recruiting
Stockholm, Sweden, 111 57
Novartis Investigative Site Recruiting
Trollhattan, Sweden, 461 85
Novartis Investigative Site Recruiting
Uddevalla, Sweden, 451 50
Taiwan
Novartis Investigative Site Recruiting
Tainan 704, Taiwan ROC, Taiwan
Novartis Investigative Site Recruiting
Chiayi County, Taiwan, 613
Novartis Investigative Site Recruiting
Niaosong Township, Taiwan, 83301
Novartis Investigative Site Recruiting
Taichung, Taiwan, 40705
Novartis Investigative Site Recruiting
Taichung, Taiwan, 40447
Novartis Investigative Site Recruiting
Taipei, Taiwan, 10002
Novartis Investigative Site Recruiting
Taipei, Taiwan, 112
Novartis Investigative Site Recruiting
Taipei County, Taiwan
Thailand
Novartis Investigative Site Recruiting
Bangkok, Thailand, 10700
Novartis Investigative Site Recruiting
Chiang Mai, Thailand, 50200
Novartis Investigative Site Recruiting
Khon Kaen, Thailand, 40002
Novartis Investigative Site Recruiting
Songkla, Thailand, 90110
Turkey
Novartis Investigative Site Recruiting
Ankara, Turkey, 06100
Novartis Investigative Site Recruiting
Ankara, Turkey, 06490
Novartis Investigative Site Recruiting
Istanbul, Turkey, 34854
Novartis Investigative Site Recruiting
Istanbul, Turkey
Novartis Investigative Site Recruiting
Izmir, Turkey, 35040
Novartis Investigative Site Recruiting
Kinikli / Denizli, Turkey, 20070
Novartis Investigative Site Recruiting
Manisa, Turkey, 45040
Novartis Investigative Site Recruiting
Mersin, Turkey, 33079
United Kingdom
Novartis Investigative Site Recruiting
Stockton, Cleveland, United Kingdom, TS19 8PE
Novartis Investigative Site Recruiting
Midsomer Norton, Radstock, United Kingdom, BA3 2UH
Novartis Investigative Site Recruiting
Axbridge, Somerset, United Kingdom, BS26 2BJ
Novartis Investigative Site Recruiting
Taunton, Somerset, United Kingdom, TA1 5DA
Novartis Investigative Site Recruiting
South Shields, Tyne and Wear, United Kingdom, NE34 0PL
Novartis Investigative Site Recruiting
Crawley, West Sussex, United Kingdom, RH10 7DX
Novartis Investigative Site Recruiting
Birmingham, United Kingdom, B15 2TH
Novartis Investigative Site Recruiting
Bradford, United Kingdom, BD9 6RJ
Novartis Investigative Site Recruiting
Cambridge, United Kingdom, CB7 5JD
Novartis Investigative Site Recruiting
Chester, United Kingdom, CH2 1UL
Novartis Investigative Site Recruiting
Darlington, United Kingdom, DL3 6HX
Novartis Investigative Site Recruiting
Huntingdon, United Kingdom, PE29 6NT
Novartis Investigative Site Recruiting
Lancashire, United Kingdom, FY3 7EN
Novartis Investigative Site Recruiting
Leeds, United Kingdom, LS9 7TF
Novartis Investigative Site Recruiting
London, United Kingdom, EC14 7BE
Novartis Investigative Site Recruiting
Newcastle-upon-Tyne, United Kingdom, NE7 7DN
Novartis Investigative Site Recruiting
Newport, United Kingdom, P030 5TG
Novartis Investigative Site Recruiting
Southampton, United Kingdom, SO16 6YD
Novartis Investigative Site Recruiting
Tyne & Wear, United Kingdom, NE29 8NH
Novartis Investigative Site Recruiting
Wiltshire, United Kingdom, SN15 2SB
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT01782326     History of Changes
Other Study ID Numbers: CQVA149A2318
Study First Received: January 30, 2013
Last Updated: June 2, 2014
Health Authority: European Union: European Medicines Agency

Keywords provided by Novartis:
COPD, QVA149

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Fluticasone
Salmeterol
Adrenergic Agents
Adrenergic Agonists
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Anti-Allergic Agents
Anti-Asthmatic Agents
Anti-Inflammatory Agents
Autonomic Agents
Bronchodilator Agents
Dermatologic Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 21, 2014